Drug Trial Radar · NCT06911034
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Feb 1, 2024
Primary completion
Jul 31, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- CMH Multan Institute of Medical SciencesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial aimed to determine whether intravenous ferric carboxymaltose is more useful than iron sucrose for treating anemia in pregnant women. The main question it aimed to answer was: Is intravenous ferric carboxymaltose is more useful than iron sucrose for treating iron deficiency anemia in pregnant women. Sixty pregnant women with iron deficiency anemia were enrolled to one of two intravenous treatments. * Participants in ferrous carboxymaltose group received a maximum dose of 1000 mg per sitting diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. * Participants in iron sucrose group were administered an infusion of 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week.
Conditions
- Iron Deficiency Anemia (IDA)
- Pregnancy
Interventions
Iron CarboxymaltoseDrug
In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
Iron Sucrose InjectionDrug
Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in hemoglobinTime frame: After three weeks of completing parenteral iron therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cmh Multan Institute of Medical Sciences
Multan, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.